The US Food and Drug Administration (FDA) has approved the immunotherapy drug Tecentriq (atezolizumab) for the treatment of small cell lung cancer (SCLC).
The US Food and Drug Administration had approved the immunotherapy drug Opdivo (nivolumab) to treat people with small cell lung cancer (SCLC).